Micromet, Inc. is a biopharmaceutical company that develops antibody-based therapies for the treatment of disaeases such as cancer, kidney disease, rheumatoid arthritis, and bone disease.

According to the Complaint filed on February 08, 2012, this action arises out of the Defendant’s decision to sell the Company to another company at an inadequate and unfair price following a grossly unfair process pursuant to an Agreement and Plan of Merger dated January 25, 2012.

On April 30, 2012, the Plaintiff filed a Notice voluntarily dismissing this action without prejudice.